ישראל - עברית - Ministry of Health

novartis israel ltd - imatinib as mesylate - טבליות מצופות פילם - imatinib as mesylate 400 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

ישראל - עברית - Ministry of Health

novartis israel ltd - letrozole - טבליות מצופות פילם - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 0.5 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 0.75 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 0.25 mg - everolimus - everolimus - kidney and heart transplantationcertican ® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - fingolimod as hydrochloride - קפסולה קשיחה - fingolimod as hydrochloride 0.5 mg - fingolimod - fingolimod - gilenya is indicated for the treatment of patients with relapsing forms of multiple sclerosis ( ms ) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disabiliry.